Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Breast Cancer
Interventions: DRUG: Milademetan|BEHAVIORAL: Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
Sponsor: Institut Curie
Collaborators: Rain Oncology Inc